No Comments

I’m still preparing my end of year trend posting, so for now I’ll just point you in the direction of a short article on the future of healthcare that I wrote for  Pharmac’s (the New Zealand government’s pharmaceutical purchasing agency) Annual Review (PDF, 1.5 MB).

The Pharmaceutical industry is in an interesting period of change. About US$100 Billion “patent dividend” is anticipated over the next few years as some major blockbuster drugs come off patent, so pharmaceutical companies are looking to where they could generate new income. Some companies are big on mergers and acquisitions, others are trying out more open innovation models. Some Big Pharma companies are moving into generic medicines, others are heading upstream to become more involved in diagnostics, and some may transform into healthcare management companies. Smaller pharmaceutical firms and biotechnology companies are producing more of the pharmaceuticals now.

Meanwhile regulators and pharmaceutical purchasers around the world are demanding more information on the comparative effectiveness of new medicines. Better outcomes, not just more pills is what they are looking for.  Generating that information adds more time and money to developing new treatments. Some patient lobby groups though are wanting access to drugs quicker, even if critical clinical data is lacking.

“Electronic medicine” is being viewed as a means to help reduce (or at least better contain) healthcare costs, through better management and smarter use of patient medical records (NZ doctors are already good users of electronic records). The amount of information about patients is set to skyrocket, so there is going to be a lot more information to manage, and mine for better treatment options. IBM, though, has noted that doctors now often have more information than they know what to do with [PDF, 0.9 MB].

Lots of applications for smart phones and tablet computers are appearing. These are intended to help folks better manage their own health. However, the  health apps field has been called the “wild west” because many of the apps have not demonstrated clinical validity or sought FDA approval.

The future will be interesting. Patients will be  expecting more personalised care, while major healthcare providers will be ever more involved in number crunching and analytics to determine the treatment options that best meet their performance requirements.